239 related articles for article (PubMed ID: 11494158)
21. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation.
Cummins NW; Deziel PJ; Abraham RS; Razonable RR
Transpl Infect Dis; 2009 Feb; 11(1):20-7. PubMed ID: 18811629
[TBL] [Abstract][Full Text] [Related]
22. Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype.
Sinclair E; Tan QX; Sharp M; Girling V; Poon C; Natta MV; Jabs DA; Inokuma M; Maecker HT; Bredt B; Jacobson MA;
J Infect Dis; 2006 Dec; 194(11):1537-46. PubMed ID: 17083038
[TBL] [Abstract][Full Text] [Related]
23. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.
Avetisyan G; Larsson K; Aschan J; Nilsson C; Hassan M; Ljungman P
Bone Marrow Transplant; 2006 Nov; 38(10):687-92. PubMed ID: 17001346
[TBL] [Abstract][Full Text] [Related]
24. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
Gallez-Hawkins G; Thao L; Lacey SF; Martinez J; Li X; Franck AE; Lomeli NA; Longmate J; Diamond DJ; Spielberger R; Forman SJ; Zaia JA
Biol Blood Marrow Transplant; 2005 Nov; 11(11):890-902. PubMed ID: 16275592
[TBL] [Abstract][Full Text] [Related]
25. Onset and duration of cytomegalovirus immediate early 1 mRNA expression in the blood of renal transplant recipients.
Goossens VJ; Christiaans MH; Blok MJ; Terporten PH; Sillekens P; Lukacsi A; Van Hooff JP; Bruggeman CA
J Med Virol; 2004 Jan; 72(1):94-101. PubMed ID: 14635016
[TBL] [Abstract][Full Text] [Related]
26. Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry.
Maecker HT; Maino VC
Hum Immunol; 2004 May; 65(5):493-9. PubMed ID: 15172449
[TBL] [Abstract][Full Text] [Related]
27. Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy.
Zandvliet ML; Falkenburg JH; Jedema I; Willemze R; Guchelaar HJ; Meij P
J Immunother; 2009 Jun; 32(5):513-23. PubMed ID: 19609244
[TBL] [Abstract][Full Text] [Related]
28. Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant.
Seropian S; Ferguson D; Salloum E; Cooper D; Landry ML
Bone Marrow Transplant; 1998 Sep; 22(5):507-9. PubMed ID: 9733277
[TBL] [Abstract][Full Text] [Related]
29. The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients.
Nordøy I; Müller F; Nordal KP; Rollag H; Lien E; Aukrust P; Froland SS
J Infect Dis; 2000 Jan; 181(1):51-7. PubMed ID: 10608750
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of human Cytomegalovirus infection by antigenemia and viremia in the first 100 days following renal transplantation and relation to antiviral strategies.
Terlizzi ME; Costa C; Astegiano S; Sidoti F; Vendrame R; Segoloni GP; Bergallo M; Cavallo R
Minerva Med; 2008 Jun; 99(3):231-9. PubMed ID: 18497721
[TBL] [Abstract][Full Text] [Related]
31. Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation.
von Müller L; Schliep C; Storck M; Hampl W; Schmid T; Abendroth D; Mertens T
J Med Virol; 2006 Mar; 78(3):394-9. PubMed ID: 16419118
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model.
Devaud C; Bilhere E; Loizon S; Pitard V; Behr C; Moreau JF; Dechanet-Merville J; Capone M
Cancer Res; 2009 May; 69(9):3971-8. PubMed ID: 19383918
[TBL] [Abstract][Full Text] [Related]
33. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
Murray BM; Subramaniam S
Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
[TBL] [Abstract][Full Text] [Related]
34. [Evaluation of viral load and antigenemia as markers for relapse cytomegalovirus infection in renal transplant recipients].
Franco A; Serrano R; Gimeno A; de Juan J; Merino E; Jiménez del Cerro L; Olivares J
Nefrologia; 2007; 27(2):202-8. PubMed ID: 17564566
[TBL] [Abstract][Full Text] [Related]
35. Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study.
Yao J; Bechter C; Wiesneth M; Härter G; Götz M; Germeroth L; Guillaume P; Hasan F; von Harsdorf S; Mertens T; Michel D; Döhner H; Bunjes D; Schmitt M; Schmitt A
Clin Infect Dis; 2008 May; 46(10):e96-105. PubMed ID: 18419478
[TBL] [Abstract][Full Text] [Related]
36. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
37. Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation.
Morita-Hoshi Y; Heike Y; Kawakami M; Sugita T; Miura O; Kim SW; Mori SI; Fukuda T; Tanosaki R; Tobinai K; Takaue Y
Bone Marrow Transplant; 2008 Mar; 41(6):515-21. PubMed ID: 18026143
[TBL] [Abstract][Full Text] [Related]
38. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
39. Inflammatory bowel disease after liver transplantation: a role for cytomegalovirus infection.
Verdonk RC; Haagsma EB; Van Den Berg AP; Karrenbeld A; Slooff MJ; Kleibeuker JH; Dijkstra G
Scand J Gastroenterol; 2006 Feb; 41(2):205-11. PubMed ID: 16484126
[TBL] [Abstract][Full Text] [Related]
40. Strategic use of an adenoviral vector for rapid and efficient ex vivo-generation of cytomegalovirus pp65-reactive cytolytic and helper T cells.
Forsberg O; Carlsson B; Tötterman TH; Essand M
Br J Haematol; 2008 Apr; 141(2):188-99. PubMed ID: 18307565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
